Antibiotics target energy-consuming processes. As such, perturbations to bacterial metabolic
homeostasis are significant consequences of treatment. Here, we describe three postulates …

Successful treatment of tuberculosis (TB) can be hampered by Mycobacterium tuberculosis
populations that are temporarily able to survive antibiotic pressure in the absence of drug …

Bacteriostatic and bactericidal antibiotic treatments result in two fundamentally different
phenotypic outcomes—the inhibition of bacterial growth or, alternatively, cell death. Most …

Tuberculosis (TB), caused by the intracellular pathogen Mycobacterium tuberculosis,
remains one of the leading causes of mortality across the world. There is an urgent …

Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment
of multi-drug resistant tuberculosis in decades. In vitro resistance to BDQ was previously …

Metabolism was once relegated to the supply of energy and biosynthetic precursors, but it
has now become clear that it is a specific mediator of nearly all physiological processes. In …

In experimental evolution, laboratory-controlled conditions select for the adaptation of
species, which can be monitored in real time. Despite the current popularity of such …

Abstract Bedaquiline (BDQ), a first-in-class diarylquinoline anti-tuberculosis drug, and its
analogue, TBAJ-587, prevent the growth and proliferation of Mycobacterium tuberculosis by …

Multidrug-resistant tuberculosis (MDR-TB) is more prevalent today than at any other time in
human history. Bedaquiline (BDQ), a novel Mycobacterium-specific adenosine triphosphate …

Abstract The Mycobacterium tuberculosis (Mtb) electron transport chain (ETC) has received
significant attention as a drug target, however its vulnerability may be affected by its flexibility …